Phase II Trial: Mirvetuximab Soravtansine & Olaparib Maintenance in Recurrent Ovarian Cancer

University of Colorado, Denver is evaluating a maintenance therapy combining mirvetuximab soravtansine—a FOLR1-directed ADC—with olaparib in patients with platinum-sensitive, recurrent high-grade ovarian, peritoneal, and fallopian tube cancers. In this trial, patients receive mirvetuximab at 5 mg/kg IV every 3 weeks along with olaparib 300 mg orally twice daily until disease progression, toxicity, or other discontinuation criteria are met.